GoAI
Get started
biote Corp. logo

biote Corp.

BTMD

NASDAQHealthcareMedical - Care Facilities

Open in GoAI

Previous close

$1.61

+$0.13 · +8.78%

Aug 21, 4:00 PM ET

Pre-market

$1.4459

−$0.1641 · -10.19%

Aug 24, 7:07 AM ET

BTMD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

75

Undervalued

Momentum

44

Neutral

Sentiment

72

Bullish

Risk resilience

23

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
US
CEO
Robert C. Peterson
Listed since
Apr 28, 2021
Employees
223

Market position

Day range

Current $1.61

52-week range

Current $1.61

Open
$1.49
Previous close
$1.48
Volume
275.36K
0.99× average
Average volume
277.73K
Average daily volume
Market cap
71.01M USD
Beta
1.65
Market reference 1
50-day average
$2.044
-21.23% below average
200-day average
$2.1525
-25.20% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
167.14M USD
P/E (TTM)
9.59×
P/B (TTM)
-0.7×
P/S (TTM)
0.39×
EV / EBITDA
3.2×
Earnings yield
33.25%
Free cash flow yield
37.10%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
60.23%
Operating margin
8.04%
Net margin
3.19%
Return on equity
-46.20%
Return on assets
25.13%
Return on invested capital
43.03%

Financial health

Debt / equity
-1.96×
Current ratio
1.22×
Altman Z-score
2.16
Piotroski F-score
7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends82%39%-4%-48%Gross margin, FY2021: 64.98%Gross margin, FY2022: 66.92%Gross margin, FY2023: 68.78%Gross margin, FY2024: 70.52%Gross margin, FY2025: 71.46%Operating margin, FY2021: 24.79%Operating margin, FY2022: -36.81%Operating margin, FY2023: 15.46%Operating margin, FY2024: 16.03%Operating margin, FY2025: 18.50%Net margin, FY2021: 23.40%Net margin, FY2022: -0.59%Net margin, FY2023: 1.79%Net margin, FY2024: 1.60%Net margin, FY2025: 14.07%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 64.98%. Gross margin FY2022 66.92%. Gross margin FY2023 68.78%. Gross margin FY2024 70.52%. Gross margin FY2025 71.46%. Operating margin FY2021 24.79%. Operating margin FY2022 -36.81%. Operating margin FY2023 15.46%. Operating margin FY2024 16.03%. Operating margin FY2025 18.50%. Net margin FY2021 23.40%. Net margin FY2022 -0.59%. Net margin FY2023 1.79%. Net margin FY2024 1.60%. Net margin FY2025 14.07%.

Income trends

Revenue

192.22M USD-2.52%

Operating income

35.55M USD+12.46%

Net income

27.05M USD+756.67%
Income trends across reported periods222.98M USD119.82M USD16.65M USD−86.51M USDRevenue, FY2021: 139.4M USDRevenue, FY2022: 164.96M USDRevenue, FY2023: 185.36M USDRevenue, FY2024: 197.19M USDRevenue, FY2025: 192.22M USDOperating income, FY2021: 34.56M USDOperating income, FY2022: −60.72M USDOperating income, FY2023: 28.66M USDOperating income, FY2024: 31.61M USDOperating income, FY2025: 35.55M USDNet income, FY2021: 32.62M USDNet income, FY2022: −969K USDNet income, FY2023: 3.32M USDNet income, FY2024: 3.16M USDNet income, FY2025: 27.05M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 139.4M USD. Revenue FY2022 164.96M USD. Revenue FY2023 185.36M USD. Revenue FY2024 197.19M USD. Revenue FY2025 192.22M USD. Operating income FY2021 34.56M USD. Operating income FY2022 −60.72M USD. Operating income FY2023 28.66M USD. Operating income FY2024 31.61M USD. Operating income FY2025 35.55M USD. Net income FY2021 32.62M USD. Net income FY2022 −969K USD. Net income FY2023 3.32M USD. Net income FY2024 3.16M USD. Net income FY2025 27.05M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue192.22M USD197.19M USD185.36M USD164.96M USD139.4M USD
Cost of goods sold54.86M USD58.13M USD57.88M USD54.58M USD48.82M USD
Gross profit137.36M USD139.06M USD127.48M USD110.38M USD90.58M USD
Selling, general, and administrative101.81M USD107.45M USD98.83M USD171.1M USD53.96M USD
Operating expenses101.81M USD107.45M USD98.83M USD171.1M USD56.02M USD
Interest expense10.96M USD11M USD6.36M USD4.05M USD1.67M USD
Depreciation and amortization3.67M USD3.57M USD794K USD2.2M USD1.4M USD
Operating income35.55M USD31.61M USD28.66M USD−60.72M USD34.56M USD
Net income27.05M USD3.16M USD3.32M USD−969K USD32.62M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
0.74
FY2025 · +703.47% year over year
Latest fiscal-year revenue
192.22M USD
FY2025 · -2.52% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend4.752.981.21-0.56FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend202.97M179.85M156.73M133.62MFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

7 ratings
Strong buy00%
Buy686%
Hold114%
Sell00%
Strong sell00%

Recent analyst actions

5 institutions
Craig-HallummaintainBuy

BTMD news

seekingalpha.com

biote Corp. (BTMD) Q2 2026 Earnings Call Transcript

biote Corp. (BTMD) Q2 2026 Earnings Call Transcript

Read source
zacks.com

biote Corp. (BTMD) Reports Break-Even Earnings for Q2

biote Corp. (BTMD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.1 per share a year ago.

Read source
marketbeat.com

biote Q2 Earnings Call Highlights

biote NASDAQ: BTMD reported lower second-quarter revenue and a net loss as a voluntary recall of certain hormone pellets supplied by Asteria Health disrupted procedure volumes, while management said supply conditions…

Read source
businesswire.com

Biote Reports Second Quarter 2026 Financial Results

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced financial results…

Read source
businesswire.com

Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners' patients,…

Read source
businesswire.com

Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer

IRVING, Texas--(BUSINESS WIRE)--Biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally…

Read source

BTMD peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding BTMD

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.87M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
559.42K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
184.07K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
149.1K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
95.04K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%
Applied Finance IVS US SMID ETF logoApplied Finance IVS US SMID ETFIVSS
Market value
5.58K
Weight
0.02%
AUM
12.69M USD
Expense ratio
0.59%
Price / 1D
$30.6102+0.79%

Continue in GoAI

Research BTMD

research.disclaimer